MiMedx Group (NASDAQ:MDXG) Reaches New 1-Year Low Following Analyst Downgrade

MiMedx Group, Inc (NASDAQ:MDXG) hit a new 52-week low during mid-day trading on Tuesday after Lake Street Capital lowered their price target on the stock from $12.00 to $10.00. Lake Street Capital currently has a buy rating on the stock. MiMedx Group traded as low as $5.16 and last traded at $5.1350, with a volume of 135418 shares traded. The stock had previously closed at $5.42.

A number of other brokerages also recently commented on MDXG. Mizuho reduced their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Finally, Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Insider Activity at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of MiMedx Group stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $7.42, for a total value of $432,586.00. Following the completion of the sale, the insider directly owned 236,982 shares in the company, valued at $1,758,406.44. This trade represents a 19.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.70% of the stock is owned by insiders.

Hedge Funds Weigh In On MiMedx Group

Several hedge funds have recently made changes to their positions in MDXG. Trigran Investments Inc. grew its stake in MiMedx Group by 10.4% during the 2nd quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock valued at $51,266,000 after purchasing an additional 790,901 shares during the last quarter. First Light Asset Management LLC lifted its holdings in shares of MiMedx Group by 89.5% during the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after purchasing an additional 1,725,458 shares during the period. Dimensional Fund Advisors LP boosted its position in MiMedx Group by 4.3% in the third quarter. Dimensional Fund Advisors LP now owns 2,382,333 shares of the company’s stock valued at $16,628,000 after buying an additional 99,084 shares during the last quarter. Punch & Associates Investment Management Inc. increased its holdings in MiMedx Group by 1.6% in the 3rd quarter. Punch & Associates Investment Management Inc. now owns 2,005,014 shares of the company’s stock worth $13,995,000 after buying an additional 31,082 shares during the period. Finally, Nantahala Capital Management LLC acquired a new position in MiMedx Group in the 3rd quarter worth approximately $10,237,000. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Stock Up 1.7%

The company has a current ratio of 4.41, a quick ratio of 3.95 and a debt-to-equity ratio of 0.07. The business’s 50-day simple moving average is $6.62 and its 200-day simple moving average is $6.88. The company has a market capitalization of $802.70 million, a PE ratio of 20.07 and a beta of 1.57.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.08. The company had revenue of $113.73 million during the quarter, compared to analysts’ expectations of $94.74 million. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%. As a group, equities research analysts anticipate that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.